Familial Hypertrophic Cardiomyopathy: Diagnosis and Management

Hypertrophic cardiomyopathy (HCM) is widely recognized as one of the most common inheritable cardiac disorders. Since its initial description over 60 years ago, advances in multimodality imaging and translational genetics have revolutionized our understanding of the disorder. The diagnosis and management of patients with HCM are optimized with a multidisciplinary approach. This, along with increased safety and efficacy of medical, percutaneous, and surgical therapies for HCM, has afforded more personalized care and improved outcomes for this patient population. In this review, we will discuss our modern understanding of the molecular pathophysiology that underlies HCM. We will describe the range of clinical presentations and discuss the role of genetic testing in diagnosis. Finally, we will summarize management strategies for the hemodynamic subtypes of HCM with specific emphasis on the rationale and evidence for the use of implantable cardioverter defibrillators, septal reduction therapy, and cardiac myosin inhibitors.

Automated summary

Hypertrophic cardiomyopathy (HCM) is a common inheritable cardiac disorder, and advances in imaging and genetics have greatly improved our understanding of the disease. A multidisciplinary approach to diagnosis and treatment, along with advancements in medical, percutaneous, and surgical therapies, has led to better outcomes and personalized care for patients with HCM.